

Chemical constituents of the egg cases of *Tenodera angustipennis* (Mantidis ootheca) with intracellular reactive oxygen species scavenging activity

Seung Mok Ryu,¹ Hyeon-hwa Nam,¹ Joong Sun Kim,¹ Jun-ho Song,¹ Young Hye Seo,¹ Hyo Seon Kim,¹ A Yeong Lee,¹ Wook Jin Kim,¹ Dongho Lee,² Byeong Cheol Moon,¹ and Jun Lee^{1,*}.

¹Herbal Medicine Resources Research Center, Korea Institute of Oriental Medicine (KIOM), Naju 58245, Republic of Korea

²Department of Plant Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea

Authors to whom correspondence should be addressed.

*Tel: +82-61-338-7129. Fax: +82-61-338-7135. E-mail: junlee@kiom.re.kr (Jun Lee).

Table of contents

| | |
|---|----|
| Figure S1: Structures of known compounds (3–15) | 3 |
| Figure S2: Spectroscopic data of known compounds (3–14) | 4 |
| Figure S3: GC-MS spectrum of compound 15 | 7 |
| Figure S4: ¹ H NMR spectrum of tenoderin A (1) (CD ₃ OD, 500 MHz) | 8 |
| Figure S5: ¹³ C NMR spectrum of tenoderin A (1) (CD ₃ OD, 125 MHz) | 9 |
| Figure S6: HSQC NMR spectrum of tenoderin A (1) (CD ₃ OD) | 10 |
| Figure S7: HMBC NMR spectrum of tenoderin A (1) (CD ₃ OD) | 11 |
| Figure S8: COSY NMR spectrum of tenoderin A (1) (CD ₃ OD) | 12 |
| Figure S9: HRESIMS spectrum of tenoderin A (1) (CD ₃ OD) | 13 |
| Figure S10: ¹ H NMR spectrum of tenoderin B (2) (CD ₃ OH, 500 MHz) | 14 |
| Figure S11: ¹³ C NMR spectrum of tenoderin B (2) (CD ₃ OH, 125 MHz) | 15 |
| Figure S12: HSQC NMR spectrum of tenoderin B (2) (CD ₃ OH) | 16 |
| Figure S13: HMBC NMR spectrum of tenoderin B (2) (CD ₃ OH) | 17 |
| Figure S14: COSY NMR spectrum of tenoderin B (2) (CD ₃ OH) | 18 |
| Figure S15: HRESIMS spectrum of tenoderin B (2) | 19 |
| Figure S16: Stereomicroscope micrographs showing the ootheca morphology of <i>Tenodera angustipennis</i> . (A) Dorsal view; (B) Lateral view; (C) Surface pattern on lateral view; Scale bars = 1 cm (A, B). 1 mm (C) | 20 |
| Table S1: Screening of the antioxidant activity of extract (100 µg/mL) and isolated compounds (100 µM) | 21 |

Figure S1: Structures of known compounds (3–15)




Figure S2: Spectroscopic data of known compounds (3–14)

N-acetyldopamine (**3**): ESIMS (positive) m/z 196 $[M + H]^+$; ESIMS (negative) m/z 194 $[M - H]^-$; 1H NMR (CD_3OD , 500 MHz) δ 6.68 (1H, d, $J = 8.1$ Hz, H-5), 6.64 (1H, d, $J = 2.1$ Hz, H-2), 6.52 (1H, dd, $J = 8.0, 2.1$ Hz, H-6), 3.31 (2H, overlap with MeOD, H-8), 2.62 (2H, t, $J = 7.4$ Hz, H-7), 1.90 (3H, s, H-10); ^{13}C NMR (CD_3OD , 125 MHz) δ 173.4 (C-9), 146.4 (C-3), 144.9 (C-4), 132.2 (C-1), 121.2 (C-6), 117.0 (C-2), 116.5 (C-5), 42.6 (C-8), 36.0 (C-7), 22.7 (C-10).

2-oxo-*N*-acetyldopamine (**4**): ESIMS (positive) m/z 210 $[M + H]^+$; ESIMS (negative) m/z 208 $[M - H]^-$; 1H NMR (CD_3OD , 500 MHz) δ 7.45 (1H, d, $J = 8.7$ Hz, H-6), 7.42 (1H, s, H-2), 6.84 (1H, d, $J = 8.2$ Hz, H-5), 4.60 (2H, s, H-8), 2.05 (3H, s, H-10); ^{13}C NMR (CD_3OD , 125 MHz) δ 194.9 (C-7), 173.9 (C-9), 152.8 (C-4), 146.8 (C-3), 128.7 (C-1), 122.9 (C-6), 116.2 (C-5), 115.8 (C-2), 46.9 (C-8), 22.6 (C-10).

4-hydroxybenzaldehyde (**5**): ESIMS (positive) m/z 123 $[M + H]^+$; ESIMS (negative) m/z 121 $[M - H]^-$; 1H NMR (CD_3OD , 500 MHz) δ 9.79 (1H, s, H-7), 7.80 (2H, d, $J = 8.7$ Hz, H-2 and H-6), 6.94 (2H, d, $J = 8.5$ Hz, H-3 and H-5); ^{13}C NMR (CD_3OD , 125 MHz) δ 193.0 (C-7), 165.4 (C-4), 133.6 (C-2 and C-6), 130.5 (C-1), 117.0 (C-3 and C-5).

4-hydroxybenzoic acid (**6**): ESIMS (positive) m/z 139 $[M + H]^+$; ESIMS (negative) m/z 137 $[M - H]^-$; 1H NMR (CD_3OD , 500 MHz) δ 7.87 (2H, d, $J = 8.4$ Hz, H-2 and H-6), 6.82 (2H, d, $J = 8.1$ Hz, H-3 and H-5); ^{13}C NMR (CD_3OD , 125 MHz) δ 169.8 (C-7), 163.5 (C-4), 133.3 (C-2 and C-6), 123.7 (C-1), 116.2 (C-3 and C-5).

Apocynin (**7**): ESIMS (positive) m/z 167 $[M + H]^+$; ESIMS (negative) m/z 165 $[M - H]^-$; 1H NMR (CD_3OD , 500 MHz) δ 7.56 (1H, dd, $J = 8.5, 2.1$ Hz, H-6), 7.42 (1H, s, H-2), 7.02 (1H, d, $J = 8.4$ Hz, H-5), 3.94 (3H, s, OCH_3 -3), 2.53 (3H, s, H-8); ^{13}C NMR (CD_3OD , 125 MHz) δ 199.7 (C-7), 153.8 (C-4), 147.7 (C-3), 131.7 (C-1), 123.2 (C-6), 115.7 (C-5), 111.7 (C-2), 56.5 (OCH_3 -3), 26.4 (C-8).

Benzoic acid (**8**): ESIMS (negative) m/z 121 $[M - H]^-$; 1H NMR (CD_3OD , 500 MHz) δ 8.01 (2H, d, $J = 8.0$ Hz, H-2 and H-6), 7.57 (1H, t, $J = 7.4$ Hz, H-4), 7.46 (1H, t, $J = 7.5$ Hz, H-3 and H-5); ^{13}C NMR (CD_3OD , 125 MHz) δ 170.1 (C-7), 133.9 (C-2 and C-6), 131.2 (C-4), 130.6 (C-1), 129.6 (C-3 and C-5).

Protocatechuic acid (**9**): ESIMS (positive) m/z 155 $[M + H]^+$; ESIMS (negative) m/z 153 $[M - H]^-$; 1H NMR (CD_3OD , 500 MHz) δ 7.42 (2H, overlap with H-2 and H-6), 6.79 (1H, d, $J = 7.9$ Hz, H-5); ^{13}C NMR (CD_3OD , 125 MHz) δ 170.6 (C-7), 151.6 (C-4), 146.2 (C-3), 124.1 (overlap, C-1 and C-6), 117.9 (C-2), 115.9 (C-5).

4-hydroxyphenylacetic acid (**10**): ESIMS (negative) m/z 151 $[M - H]^-$; 1H NMR (CD_3OD , 500 MHz) δ 7.08 (2H, d, $J = 8.3$ Hz, H-2 and H-6), 6.72 (2H, d, $J = 8.5$ Hz, H-3 and H-5), 3.50 (2H, s, H-7); ^{13}C NMR (CD_3OD , 125 MHz) δ 176.2 (C-8), 157.6 (C-4), 131.5 (C-2 and C-6), 127.1 (C-1), 116.3 (C-3 and C-5), 41.7 (C-7).

(*S*)-1-phenylentane-1,2-diol (**11**): $[\alpha]_D^{26} +10.8$ (c 0.01, MeOH); ESIMS (positive) m/z 139 $[M + H]^+$; ESIMS (negative) m/z 137 $[M - H]^-$; 1H NMR (CD_3OD , 500 MHz) δ 7.37 (2H, d, $J = 7.1$ Hz, H-2 and H-6), 7.33 (2H, t, $J = 7.5$ Hz, H-3 and H-5), 7.25 (1H, t, $J = 7.3$ Hz, H-4), 4.68 (1H, t, $J = 5.5$ Hz, H-7), 3.60 (2H, overlap with MeOH, H-8); ^{13}C NMR (CD_3OD , 125 MHz) δ 143.5 (C-1), 129.4 (C-3 and C-5), 128.7 (C-4), 127.6 (C-6), 76.1 (C-7), 68.9 (C-8).

4-hydroxyphenylglyoxylic acid amide (**12**): ESIMS (negative) m/z 164 $[M - H]^-$; ^1H NMR (CD_3OD , 500 MHz) δ 8.01 (2H, d, $J = 8.8$ Hz, H-2 and H-6), 6.87 (2H, d, $J = 8.9$ Hz, H-3 and H-5); ^{13}C NMR (CD_3OD , 125 MHz) δ 189.8 (C-7), 170.2 (C-8), 165.4 (C-3), 134.3 (C-2 and C-6), 126.1 (C-1), 116.7 (C-3 and C-5).

(\pm)-hydroxybutenolide (**13**): Racemic mixture, ESIMS (positive) m/z 193 $[M + H]^+$; ESIMS (negative) m/z 191 $[M - H]^-$; ^1H NMR (CD_3OD , 500 MHz) δ 7.67 (2H, d, $J = 8.8$ Hz, H-2 and H-6), 6.86 (2H, d, $J = 8.8$ Hz, H-3 and H-5), 6.50 (1H, s, H-2'), 6.32 (1H, s, H-4'); ^{13}C NMR (CD_3OD , 125 MHz) δ 174.3 (C-5'), 165.8 (C-3'), 162.3 (C-4), 131.5 (C-2 and C-6), 122.4 (C-1), 117.0 (C-3 and C-5), 111.9 (C-4'), 100.1 (C-2').

Scoparone (**14**): ESIMS (positive) m/z 207 $[M + H]^+$; ^1H NMR (CD_3OD , 500 MHz) δ 7.90 (1H, d, $J = 9.4$ Hz, H-4), 7.15 (1H, s, H-5), 7.00 (1H, s, H-8), 6.27 (1H, d, $J = 9.4$ Hz, H-3), 3.93 (3H, s, OCH_3 -7), 3.88 (3H, s, OCH_3 -6); ^{13}C NMR (CD_3OD , 125 MHz) δ 164.0 (C-2), 155.0 (C-7), 151.5 (C-8a), 148.3 (C-6), 146.1 (C-4), 113.7 (C-3), 113.3 (C-4a), 110.1 (C-5), 101.2 (C-8), 57.0 (OCH_3 -7), 57.0 (OCH_3 -6).

Figure S3: GC-MS spectrum of compound **15**




Figure S4: ^1H NMR spectrum of tenoderin A (1) (CD_3OD , 500 MHz)




Figure S5: ^{13}C NMR spectrum of tenoderin A (**1**) (CD_3OD , 125 MHz)




Figure S6: HSQC NMR spectrum of tenoderin A (**1**) (CD₃OD)




Figure S7: HMBC NMR spectrum of tenoderin A (1) (CD₃OD)




Figure S8: COSY NMR spectrum of tenoderin A (**1**) (CD₃OD)





Figure S9: HRESIMS spectrum of tenoderin A (1) (CD₃OD)

Elemental Composition Report

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0
 Element prediction: Off
 Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions
 1273 formula(e) evaluated with 9 results within limits (up to 50 best isotopic matches for each mass)
 Elements Used:
 C: 0-500 H: 0-1000 N: 0-200 O: 0-200
 200805_SeoYH_SM-56-1K_Neg (0.025) Is (1.00,1.00) C20H22N2O7
 1: TOF MS ES-



Minimum: 80.00
 Maximum: 100.00

| Mass | RA | Calc. Mass | mDa | PPM | DBE | i-FIT | Norm | Conf (%) | Formula |
|----------|--------|------------|------|------|------|-------|--------|----------|----------------|
| 401.1349 | 100.00 | 401.1349 | 0.0 | 0.0 | 11.5 | 46.9 | 0.000 | 100.00 | C20 H21 N2 O7 |
| | | 401.1362 | -1.3 | -3.2 | 16.5 | 70.9 | 23.914 | 0.00 | C21 H17 N6 O3 |
| | | 401.1335 | 1.4 | 3.5 | 17.5 | 75.1 | 28.125 | 0.00 | C17 H13 N12 O |
| | | 401.1330 | 1.9 | 4.7 | 24.5 | 79.1 | 32.116 | 0.00 | C32 H17 |
| | | 401.1367 | -1.8 | -4.5 | -1.5 | 79.4 | 32.480 | 0.00 | C8 H25 N4 O14 |
| | | 401.1354 | -0.5 | -1.2 | 4.5 | 82.4 | 35.444 | 0.00 | C5 H17 N14 O8 |
| | | 401.1367 | -1.8 | -4.5 | 9.5 | 82.6 | 35.612 | 0.00 | C6 H13 N18 O4 |
| | | 401.1340 | 0.9 | 2.2 | -0.5 | 82.8 | 35.902 | 0.00 | C4 H21 N10 O12 |
| | | 401.1340 | 0.9 | 2.2 | 10.5 | 86.1 | 39.154 | 0.00 | C2 H9 N24 O2 |

Figure S10: ^1H NMR spectrum of tenoderin B (**2**) (CD_3OH , 500 MHz)




Figure S11: ^{13}C NMR spectrum of tenoderin B (**2**) (CD_3OH , 125 MHz)




Figure S12: HSQC NMR spectrum of tenoderin B (**2**) (CD₃OH)




Figure S13: HMBC NMR spectrum of tenoderin B (2) (CD₃OH)




Figure S14: COSY NMR spectrum of tenoderin B (**2**) (CD₃OH)




Figure S15: HRESIMS spectrum of tenoderin B (2)

Elemental Composition Report

Page 1

Multiple Mass Analysis: 2 mass(es) processed

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions


659 formula(e) evaluated with 4 results within limits (up to 50 best isotopic matches for each mass)

Elements Used:

C: 0-500 H: 0-1000 N: 0-200 O: 0-200

202805_SeoYH_SM-36-1K_Neg-re 326 (3.701) Cm (320:331)

1: TOF MS ES-



Minimum: 80.00
Maximum: 100.00

| Mass | RA | Calc. Mass | mDa | PPM | DBE | i-FIT | Norm | Conf (%) | Formula |
|----------|--------|------------|------|------|------|--------|--------|----------|---------------|
| 314.1042 | 100.00 | 314.1042 | 0.0 | 0.0 | 15.5 | 1134.2 | 0.060 | 94.20 | C18 H12 N5 O |
| | | 314.1028 | 1.4 | 4.5 | 10.5 | 1137.0 | 2.848 | 5.79 | C17 H16 N O5 |
| | | 314.1047 | -0.5 | -1.6 | 8.5 | 1143.9 | 9.758 | 0.01 | C3 H8 N17 O2 |
| | | 314.1034 | 0.8 | 2.5 | 3.5 | 1144.3 | 10.142 | 0.00 | C2 H12 N13 O6 |

Figure S16: Stereomicroscope micrographs showing the ootheca morphology of *Tenodera angustipennis*. (A) Dorsal view; (B) Lateral view; (C) Surface pattern on lateral view; Scale bars = 1 cm (A, B). 1 mm (C)



Table S1: Screening of the antioxidant activity of extract (100 µg/mL) and isolated compounds (100 µM)

| Compounds | Antioxidant capacity (%) | |
|-------------|----------------------------|--------------|
| | DPPH | ABTS |
| Extract | 81.99 ± 1.98 ¹⁾ | 99.74 ± 0.13 |
| 1a | 56.59 ± 0.60 | 60.56 ± 0.18 |
| 1b | 71.16 ± 0.22 | 67.77 ± 1.29 |
| 2 | 80.83 ± 0.09 | 93.13 ± 0.31 |
| 3 | 76.39 ± 2.60 | 95.87 ± 0.12 |
| 4 | 81.93 ± 0.25 | 89.53 ± 0.17 |
| 5 | -1.83 ± 0.75 | 0.93 ± 1.46 |
| 6 | 0.37 ± 0.28 | -0.12 ± 0.99 |
| 7 | 9.40 ± 0.97 | 1.59 ± 1.23 |
| 8 | -1.00 ± 0.52 | 1.39 ± 1.27 |
| 9 | 78.87 ± 0.48 | 92.38 ± 0.04 |
| 10 | 38.80 ± 1.09 | 11.45 ± 0.86 |
| 11 | 41.58 ± 0.90 | 19.05 ± 0.48 |
| 12 | -0.53 ± 1.40 | 2.06 ± 0.69 |
| 13 | -0.03 ± 1.58 | 0.37 ± 0.12 |
| 14 | -1.74 ± 1.70 | 0.37 ± 0.26 |
| 15 | -2.40 ± 1.42 | -1.79 ± 0.45 |
| Gallic acid | 82.89 ± 0.09 | 95.40 ± 0.07 |

1) Values are reported as mean ± SD (n=3)